Johnson's Monday Lab Sandbox for Insulin Receptor
From Proteopedia
| Line 1: | Line 1: | ||
==Insulin Receptor== | ==Insulin Receptor== | ||
| - | <StructureSection load='6sof' size='350' side='right' caption='Insulin Receptor with Four Insulin Bound - 6sof' scene=''> | + | <StructureSection load='6sof' size='350' side='right' caption='Insulin Receptor with Four Insulin Bound - 6sof' scene='83/839263/Intro_scene/1'> |
This is a default text for your page '''Johnson's Monday Lab Sandbox for Insulin Receptor'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | This is a default text for your page '''Johnson's Monday Lab Sandbox for Insulin Receptor'''. Click above on '''edit this page''' to modify. Be careful with the < and > signs. | ||
You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue. | ||
Revision as of 22:37, 30 March 2020
Insulin Receptor
This is a default text for your page Johnson's Monday Lab Sandbox for Insulin Receptor. Click above on edit this page to modify. Be careful with the < and > signs. You may include any references to papers as in: the use of JSmol in Proteopedia [1] or to the article describing Jmol [2] to the rescue.
Function of the ReceptorThe insulin receptor resides within the plasma membrane of insulin target cells of various organs, such as the liver, and tissues including skeletal muscle and adipose. Activation of the insulin receptor is dependent upon insulin binding. Once activated, the receptor serves as the gateway for the regulation of various cellular processes. These processes include but are not limited to glucose transport, glycogen storage, autophagy, apoptosis, and gene expression. Additionally, the insulin receptor has been associated with the development of diseases such as Alzheimer's, type II diabetes, and cancer [3]. Characterization of the structure of the insulin receptor, as well as understanding of the molecular mechanisms, which initiate a conformational change, are important for understanding the role that the insulin receptor plays within a cell and in the development of the disease. Insulin StructureThe insulin receptor is a receptor tyrosine kinase. It is a heterotetramer that is constructed from two homodimers. Each homodimer maintains an extracellular domain, transmembrane helix, and an intracellular domain. The extracellular domain is divided into subunit. The alpha subunit is characterized by two leucine-rich regions and one cysteine-rich region. The beta subunit contains three fibronectin type III domains. The alpha and beta subunits of the extracellular domains fold over one another and form a when the insulin receptor is inactivated. Upon activation, the extracellular domain undergoes a conformational change and forms a .  An additional component to the ectodomain is the alpha chain C-terminal helix [4]. The alpha-CT is a single alpha-helix and it plays an important role in insulin binding and stabilization of the "T" shape activated conformation. The alpha-CT interacts with a leucine-rich region of the alpha subunit and a fibronectin type III region of the beta subunit to form an insulin binding site [4]. The structure of the extracellular domain is stabilized through covalent bonds. The alpha subunits are linked through two disulfide bonds. Cys468 and of one alpha subunit are bound to Cys435 and of the other alpha subunit, respectively [5]. of both alpha subunits hold the two together with a disulfide bond [6]. The alpha subunit is held to the beta subunit by a disulfide bond between the [6] The insulin receptor extends intracellularly from the beta subunits of the ectodomain by way of a transmembrane helix. Intracellularly, the insulin receptor contains two tyrosine kinase domains. Insulin BindingThe insulin receptor unit has four separate sites for the insulin molecule to bind to. There are two pairs of two identical binding sites referred to as 1 and 1' and then 2 and 2'. The insulin molecules bind to these sites mostly through hydrophobic interactions, with some of the most crucial residues at sites 1 and 1' being between of the insulin receptor FnIII-1 domain [4]. At sites 2 and 2', the major residues contributing to these hydrophobic interactions are the [4]. Despite a majority of the interactions being similar, sites 1 and 1' have a higher binding affinity than sites 2 and 2' due to site one having a larger surface area (706 square angstroms) exposed for insulin to bind to compared to site 2 (394 square angstroms)[4]. The insulin molecules in site 1 and 1' have their main interactions with an in the insulin receptor. The insulin molecules in site 2 and 2' have their main interactions with the residues that comprise some of the of the insulin receptor. It was found that at least three insulin molecules would have to bind to the receptor for the receptor to take on its active “T-state” conformation [4]. The difference between the fully bound state with four insulins and the three insulin bound state is minimal compared to the difference between two and three insulins bound [4]. However, only having two insulin molecules bound was insufficient to moving the receptor to active T-state. Conformational Changes The conformational change between the inverted "V" shape and the "T" shape of the insulin receptor is induced by insulin binding. When an insulin molecule binds to site 1 of the alpha subunit, the respective protomer is recruited and a slight inward movement of the fibronectin type III domains of the beta subunit is initiated. This is accomplished by the formation of several salt bridges, specifically between Asp496, Arg498, and Asp499 of the FnIII-1 domain and Lys703, Glu706, and Asp707 in the alpha-CT [4]. Binding of insulin to both protomers establishes a full activation of the insulin receptor. This activation is demonstrated through the inward movement of both protomers. This motion has been referred to as a "hinge" motion [4] as both protomers "swing" in towards one another. As the fibronectin type III domains of the beta subunit swing inward, the alpha subunits also undergo a conformational change upon insulin binding. As insulin binds to site 1, the leucine-rich region of one protomer interacts with the alpha-CT and the FNIII-1 domains of the other protomer to form a binding site. These interactions are referred to as a tripartite interface [4]. In order for the tripartite interface to form, the alpha subunits of each protomer must undergo a "folding" motion. While there is an explanation for which conformational changes of the insulin receptor take place, there is no explanation for the mechanism by which the conformational changes are executed [4]. Type II DiabetesType II Diabetes is a chronic condition that affects about 415 million people worldwide. It is caused by insulin resistance to cells and leads to high concentrations of glucose in the bloodstream. A type II diabetic still produces insulin, but when the insulin attaches to the receptors, researchers have found that the signal that initiates autophosphorylation is not processed intracellularly. In very rare cases, this has been attributed to issues with the insulin receptor. However, why the signal is not processed intracellularly is largely unknown. There are many suspected reasons that cause certain parts of the signal cascade to lose the signal [7]. Potential reasons that could lead to these results include a sedentary lifestyle, high caloric intake, genetics, microbiome, etc. [8] Type I Diabetes is a chronic, autoimmune disease that affects insulin secretion into the bloodstream that in turn results in a high glucose concentration in the bloodstream. Since insulin is not available to signal the cells to take up the glucose from the bloodstream, the glucose remains in the bloodstream where it can cause damage to the body's organ systems. However, type I diabetics can take medical insulin not produced by their body to help regulate blood sugar levels. This is different for type II diabetics as they still produce insulin, but the cells in the body are unable to properly respond to the signal. References
Student Contributors
| ||||||||||||
